The inhibition of PDE5 is commonly used as an element in multi-compound therapy of pulmonary hypertension and impotence, whereas historically, the primary target, treatment of heart failure due to side effects, failed because of low tissue selectivity in the cardiovascular system. Here, PDE5A is linked to pulmonary arterial hypertension.